MA29393B1 - Derives d'azole sous forme d'inhibiteurs de lipase et de phospholipase - Google Patents

Derives d'azole sous forme d'inhibiteurs de lipase et de phospholipase

Info

Publication number
MA29393B1
MA29393B1 MA30299A MA30299A MA29393B1 MA 29393 B1 MA29393 B1 MA 29393B1 MA 30299 A MA30299 A MA 30299A MA 30299 A MA30299 A MA 30299A MA 29393 B1 MA29393 B1 MA 29393B1
Authority
MA
Morocco
Prior art keywords
phospholipase
azole derivatives
lipase inhibitors
azole
derivatives
Prior art date
Application number
MA30299A
Other languages
English (en)
Inventor
Gerhard Zoller
Stefan Petry
Guenter Mueller
Hubert Heuer
Norbert Tennagels
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36694158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29393(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA29393B1 publication Critical patent/MA29393B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

L'INVENTION CONCERNE DES DÉRIVÉS D'AZOLE DE FORMULE (I), DONT LES SIGNIFICATIONS SONT INDIQUÉES DANS LA DESCRIPTION, LEURS SELS POUVANT ÊTRE UTILISÉS EN PHARMACIE ET LEUR UTILISATION COMME MÉDICAMENTS.
MA30299A 2005-04-20 2007-10-12 Derives d'azole sous forme d'inhibiteurs de lipase et de phospholipase MA29393B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005018389A DE102005018389A1 (de) 2005-04-20 2005-04-20 Azolderivate als Inhibitoren von Lipasen und Phospholipasen

Publications (1)

Publication Number Publication Date
MA29393B1 true MA29393B1 (fr) 2008-04-01

Family

ID=36694158

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30299A MA29393B1 (fr) 2005-04-20 2007-10-12 Derives d'azole sous forme d'inhibiteurs de lipase et de phospholipase

Country Status (20)

Country Link
US (1) US8921404B2 (fr)
EP (1) EP1874741A1 (fr)
JP (1) JP2008536884A (fr)
KR (1) KR20080004501A (fr)
CN (1) CN101160293A (fr)
AR (1) AR053228A1 (fr)
AU (1) AU2006237127A1 (fr)
BR (1) BRPI0608495A2 (fr)
CA (1) CA2606301A1 (fr)
DE (1) DE102005018389A1 (fr)
IL (1) IL186635A0 (fr)
MA (1) MA29393B1 (fr)
MX (1) MX2007012732A (fr)
MY (1) MY142441A (fr)
NO (1) NO20075938L (fr)
NZ (1) NZ562694A (fr)
RU (1) RU2414458C2 (fr)
TW (1) TW200722421A (fr)
WO (1) WO2006111321A1 (fr)
ZA (1) ZA200707929B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2009108280A (ru) 2006-08-08 2010-09-20 Санофи-Авентис (Fr) Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение
CA2682891A1 (fr) 2007-04-05 2008-10-16 Sanofi-Aventis 5-oxo-isoxazoles utilises comme inhibiteurs de lipases et de phospholipases
CN101646655A (zh) 2007-04-05 2010-02-10 塞诺菲-安万特股份有限公司 作为脂肪酶和磷脂酶抑制剂的咪唑烷甲酰胺衍生物
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
WO2010003624A2 (fr) 2008-07-09 2010-01-14 Sanofi-Aventis Composés hétérocycliques, leurs procédés de préparation, médicaments comprenant lesdits composés et leur utilisation
US8957219B2 (en) 2008-10-17 2015-02-17 Shionogi & Co., Ltd. Acetic acid amide derivative having inhibitory activity on endothelial lipase
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
WO2011023754A1 (fr) 2009-08-26 2011-03-03 Sanofi-Aventis Nouveaux hydrates de fluoroglycoside hétéroaromatiques cristallins, substances pharmaceutiques comprenant ces composés et leur utilisation
US8754113B2 (en) 2009-12-15 2014-06-17 Shionogi & Co., Ltd. Oxadiazole derivative having endothelial lipase inhibitory activity
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
EP2582709B1 (fr) 2010-06-18 2018-01-24 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
EP2612669A4 (fr) 2010-08-31 2014-05-14 Snu R&Db Foundation Utilisation de la reprogrammation f tale d'un agoniste des ppar
EP2683699B1 (fr) 2011-03-08 2015-06-24 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2683704B1 (fr) 2011-03-08 2014-12-17 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
WO2012120054A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US9321787B2 (en) * 2011-07-07 2016-04-26 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
WO2017034420A1 (fr) * 2015-08-27 2017-03-02 Auckland Uniservices Limited Inhibiteurs des tryptophane-dioxygénases (ido1 et tdo) et leur utilisation en thérapie

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114420A1 (en) * 2000-06-28 2003-06-19 Salvati Mark E. Fused cyclic modulators of nuclear hormone receptor function
AU2002226633A1 (en) * 2001-02-02 2002-08-12 Pfizer Limited Treatment of diabetes mellitus using vardenafil
WO2003005184A2 (fr) 2001-07-04 2003-01-16 Akodi S.A. Interface utilisateur graphique possedant des fenetres web
JP2003033007A (ja) 2001-07-09 2003-01-31 Sanyo Electric Co Ltd チャージポンプ回路の制御方法
WO2003051841A2 (fr) * 2001-12-14 2003-06-26 Novo Nordisk A/S Composes ralentissant l'activite de la lipase hormono-sensible
AU2003297160A1 (en) 2002-12-18 2004-07-22 Vertex Pharmaceuticals Incorporated Benzisoxazole derivatives useful as inhibitors of protein kinases
US7217727B2 (en) * 2003-04-01 2007-05-15 Eli Lilly And Company Phospholipase inhibitors
WO2004094394A1 (fr) * 2003-04-01 2004-11-04 Eli Lilly And Company Amides de l'acide benzisothiazol-3-one-carboxylique inhibiteurs des phospholipase
US20070197610A1 (en) * 2004-03-16 2007-08-23 Janssen Pharmaceutica N.V. Benzisoxazoles
TW200633990A (en) * 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound

Also Published As

Publication number Publication date
NO20075938L (no) 2007-11-19
US20080090867A1 (en) 2008-04-17
DE102005018389A1 (de) 2006-10-26
AU2006237127A1 (en) 2006-10-26
IL186635A0 (en) 2008-01-20
NZ562694A (en) 2010-05-28
CA2606301A1 (fr) 2006-10-26
CN101160293A (zh) 2008-04-09
BRPI0608495A2 (pt) 2010-01-05
WO2006111321A1 (fr) 2006-10-26
RU2414458C2 (ru) 2011-03-20
TW200722421A (en) 2007-06-16
RU2007142657A (ru) 2009-05-27
ZA200707929B (en) 2008-12-31
AR053228A1 (es) 2007-04-25
EP1874741A1 (fr) 2008-01-09
KR20080004501A (ko) 2008-01-09
US8921404B2 (en) 2014-12-30
MY142441A (en) 2010-11-30
JP2008536884A (ja) 2008-09-11
MX2007012732A (es) 2008-03-14

Similar Documents

Publication Publication Date Title
MA29393B1 (fr) Derives d'azole sous forme d'inhibiteurs de lipase et de phospholipase
MA29856B1 (fr) Derives de diacylindazole en tant qu'inhibiteurs de lipases et de phospholipases
MA29857B1 (fr) Derives de triazolopyridine en tant qu'inhibiteurs de lipases et phospholipases
MA29858B1 (fr) Derives de carbamoylbenzotriazole en tant qu'inhibiteurs de lipases et phospholipases
MA30291B1 (fr) Derives de l'azolopyridin-3-one en tant qu'inhibiteurs de la lipase endotheliale
MA28543B1 (fr) Dérivés d'imidazole utilisés comme inhibiteurs tafia
WO2006044497A3 (fr) Composes de spiropiperidine utilises comme inhibiteurs de beta-secretase en vue du traitement de la maladie d'alzheimer
WO2007011833A3 (fr) Inhibiteurs de spiropiperidine beta-secretase pour le traitement de la maladie d'alzheimer
MA29909B1 (fr) Derives de pyridazine
WO2005004802A3 (fr) Inhibiteurs de la beta-secretase a base de n-alkyle phenylcarboxamide pour le traitement de la maladie d'alzheimer
MA31296B1 (fr) Derives d'imidazolidine carboxamide en tant qu'inhibiteurs de lipase et de phospholipase
WO2008005956A3 (fr) Inhibiteurs de pyrrolotriazine kinase
MA31433B1 (fr) Inhibiteurs de la p70 s6 kinase
WO2005004803A3 (fr) Inhibiteurs de la beta-secretase de phenylcarboxylate destines au traitement de la maladie d'alzheimer
DK1780197T3 (da) 5-Substituerede 2-phenylamino-benzamider som MEK-inhibitorer
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
EP1562897A4 (fr) Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer
EP1740559A4 (fr) Derives de phenyle 1,3,5-substitues utiles comme inhibiteurs de la beta-secretase pour le traitement de la maladie d'alzheimer
MXPA06012640A (es) Compuestos de morfolina.
WO2007106192A3 (fr) Inhibiteurs iap (inhibiteurs de l'apoptose)
WO2005032471A3 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
WO2005065195A3 (fr) Inhibiteurs de phenylamide et de pyridylamide de la beta-secretase, traitant la maladie d'alzheimer
WO2004062625A3 (fr) Inhibiteurs de beta-secretase macrocyclique pour traiter la maladie d'alzheimer
WO2008054698A3 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
MA31763B1 (fr) Inhibiteurs de kinase de type polo